Skip to main content

Table 4 Number of subjects with G6PD A and B genotypes adversely affected after primaquine treatment

From: G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients

Symptoms

G6PD A− males (n = 5)

G6PD A (n = 7)

G6PD B (n = 48)

Day 1

n (%)a

Day 3

n (%)

Day 7

n (%)

Day 1

n (%)a

Day 3

n (%)

Day 7

n (%)

Day 1

n (%)a

Day 3

n (%)

Day 7

n (%)

Jaundice

2 (40.0)

1 (20.0)

–

2 (28.6)

2 (28.6)

–

5 (10.4)

3 (6.3)

–

Respiratory difficulty

–

–

–

–

–

–

3 (6.3)

2 (4.2)

2 (4.2)

Bleeding

–

–

–

–

–

–

1 (2.1)

1 (2.1)

1 (2.1)

Edema

–

–

–

–

–

–

–

–

–

Abdominal pain

2 (40.0)

–

–

2 (28.6)

2 (28.6)

1 (14.2)

12 (25.0)

13 (27.1)

1 (2.1)

Hepatomegaly

2 (40.0)

–

–

3 (42.9)

3 (42.9)

2 (28.5)

10 (20.8)

5 (10.4)

1 (2.1)

Splenomegaly

2 (40.0)

–

–

2 (28.6)

1 (14.3)

1 (14.2)

2 (4.2)

1 (2.1)

–

Low back pain

–

–

–

–

–

1 (14.2)

17 (35.4)

8 (16.7)

3 (6.3)

Pallor

2 (40.0)

1 (20.0)

1 (20.0)

2 (28.6)

2 (28.6)

1 (14.2)

–

–

–

  1. aBefore primaquine treatment